Key result
Heart-type fatty acid-binding protein is an early biomarker of myocardial injury that complements troponins in ruling out acute coronary syndromes and risk stratifying other cardiac conditions.
Why the study?
Cardiac troponin kinetics necessitate prolonged ED observation or admission for ACS diagnosis and rule-out, highlighting the need to examine earlier markers like H-FABP.
Does H-FABP measurement improve early diagnosis and risk stratification in patients with chest pain or myocardial injury compared to standard troponins?
Design
Review
Authors
Loading...
May support earlier ACS evaluation; leaves open need for prospective trials before clinical adoption.
Does H-FABP measurement improve early diagnosis and risk stratification in patients with chest pain or myocardial injury compared to standard troponins?
H-FABP is a rapidly released biomarker that complements troponins for early diagnosis of ACS and risk stratification in heart failure and pulmonary embolism.
Goel et al. (2020) conducted a review in Acute coronary syndromes, chest pain, heart failure, acute pulmonary embolism. Heart-type fatty acid-binding protein (H-FABP) vs. Cardiac troponins (cTn) was evaluated. Heart-type fatty acid-binding protein is an early biomarker of myocardial injury that complements troponins in ruling out acute coronary syndromes and risk stratifying other cardiac conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: